Loading
Individualized connectome-guided accelerated iTBS / Depression Disorder · Interventional Study
ClinicalTrials.gov · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned double-blinded, randomized trial of personalized, accelerated intermittent-theta burst stimulation guided by individual connectome mapping in adults with treatment-resistant depression and moderate-to-high anxiety. The study has not yet enrolled participants and no results are available; it is registered to measure changes in a composite depression-anxiety ratio before and after a 1-week intensive treatment course with 1-month follow-up.
Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Depression Disorder; age from 21 Years; to 70 Years. Intervention: Dysphoric target; Anxiosomatic target. n = 36. 1 site: Singapore.
This is a planned double-blinded, randomized trial of personalized, accelerated intermittent-theta burst stimulation guided by individual connectome mapping in adults with treatment-resistant depression and moderate-to-high anxiety. The study has not yet enrolled participants and no results are available; it is registered to measure changes in a composite depression-anxiety ratio before and after a 1-week intensive treatment course with 1-month follow-up.
This is a registry record with no results posted; no efficacy, safety, or effectiveness data are reported
Once results are available, this trial may inform whether personalized, accelerated brain stimulation guided by individual functional connectivity can improve depression and anxiety outcomes more efficiently than standard approaches. The small sample size and composite outcome measure will limit immediate clinical applicability; confirmation in larger trials would be needed before changing practice.
This is a study registration without reported results; it describes a planned interventional trial that has not yet begun recruiting, so no efficacy or safety data are available for evaluation.
As stated by the source record.
Quoted from the source exactly as published.
Once results are available, this trial may inform whether personalized, accelerated brain stimulation guided by individual functional connectivity can improve depression and anxiety outcomes more efficiently than standard approaches. The small sample size and composite outcome measure will limit immediate clinical applicability; confirmation in larger trials would be needed before changing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07766291). This is a study registration, not published results. Lead sponsor: National University Hospital, Singapore. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 36 participants (ESTIMATED). Conditions: Depression Disorder. Interventions: DEVICE: Individualized connectome-guided accelerated iTBS. Primary outcome measures: Rank- Transformed Ratio of Beck Depression Inventory (BDI) to Beck Anxiety Inventory (BAI) change , Baseline (before treatment), immediately after acute treatment (after 30 treatments over 1 week), and weekly during the 1-month follow-up period.. Brief summary: This proposal seeks to carry out a double-blinded, randomized, comparative study that investigates neurobehavioral changes induced by personalized, anxiosomatic and dysphoric network guided accelerated intermittent-theta burst (iTBS) using dense functional Magnetic Resonance Imaging (fMRI) sampling in participants with treatment-resistant depression (TRD) and moderate/high levels of anxiety.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.